OrthogenRx commenced U.S. launch of TriVisc® sodium hyaluronate for the treatment of knee osteoarthritis pain in a 3-injection regimen.
The formulation has received regulatory clearance in 63 countries ex-U.S. and been administered in over 35 million doses worldwide. The company claims it to be the lowest-priced 3-injection hyaluronic acid product derived from a biofermentation process on the U.S. market.
OrthogenRx also markets GenVisc 850 5-injection. The products were developed in collaboration with Meiji Seika Pharma and subsidiary, Tedec-Meiji Farma.
OrthogenRx commenced U.S. launch of TriVisc® sodium hyaluronate for the treatment of knee osteoarthritis pain in a 3-injection regimen.
The formulation has received regulatory clearance in 63 countries ex-U.S. and been administered in over 35 million doses worldwide. The company claims it to be the lowest-priced 3-injection hyaluronic acid...
OrthogenRx commenced U.S. launch of TriVisc® sodium hyaluronate for the treatment of knee osteoarthritis pain in a 3-injection regimen.
The formulation has received regulatory clearance in 63 countries ex-U.S. and been administered in over 35 million doses worldwide. The company claims it to be the lowest-priced 3-injection hyaluronic acid product derived from a biofermentation process on the U.S. market.
OrthogenRx also markets GenVisc 850 5-injection. The products were developed in collaboration with Meiji Seika Pharma and subsidiary, Tedec-Meiji Farma.
Copy to clipboard 
